Q-omics provides the consensus-scored ASNSP3 profile across patient tissues and cancer cell-line models. ASNSP3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ASNSP3 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, ASNSP3 RNA expression shows 12,947 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where ASNSP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASNSP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASNSP3 survival associations across molecular data types. ASNSP3 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASNSP3 RNA expression–survival associations across cancer types. High ASNSP3 expression shows unfavorable associations in THCA, KICH, KIRC and LGG, but favorable associations in HNSC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ASNSP3 RNA expression.
This table summarizes ASNSP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ASNSP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASNSP3 shows lower tumor expression in KIRC and ESCA and higher tumor expression in LUAD, BRCA, PRAD and THCA. The LUAD box plot shows higher ASNSP3 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p = .001).
This table shows molecular features associated with ASNSP3 in patient tissues and cancer cell lines. In patient samples, ASNSP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
